GeneDx Unveils Largest Rare Disease Genomic Dataset, Infinity™, Promising Faster and More Accurate Pediatric Diagnoses
GeneDx Holdings Corp. (Nasdaq: WGS) has announced the upcoming introduction of its proprietary dataset, GeneDx Infinity™, at the American Academy of Pediatrics $(AAP)$ National Conference & Exhibition, taking place September 26 to 30 in Denver, CO. GeneDx Infinity is the largest rare disease dataset of its kind, comprising data from over 2.5 million genomic patients, including nearly 1 million exomes and genomes, and millions of phenotypic datapoints. The company highlights Infinity's unmatched scale, depth, and diversity, which enable more accurate and equitable genetic diagnoses, particularly for children with rare diseases. The dataset underpins GeneDx's ExomeDx and GenomeDx diagnostic tests and continues to grow in power and impact with each new test. The research results and applications of Infinity will be presented to pediatricians at the upcoming AAP conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250925284526) on September 25, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.